Metal–Organic Framework Nanocomposites in Conquering Hypoxia for Tumor Therapy
Source abstract
Abstract
Abstract Hypoxia, as a distinctive feature of tumors, is closely related to tumor recurrence, metastasis, and treatment resistance. Metal–organic framework (MOF) exhibits an increasing number of advantages in cancer therapy owing to its porous structure, large specific surface area, and tunable function. The MOF nanocomposites constructed by adjusting components can effectively overcome tumor hypoxia and significantly enhance the anti‐tumor effect. In this review, the hypoxic characteristics of tumors and current strategies for constructing MOF nanocomposites that can overcome tumor hypoxia are summarized, including for delivering O2 or endogenously generating O2 to elevate intra‐tumor O2 content; inhibiting HIF‐1 and its induced products to alleviate tumor hypoxia; reducing cellular aerobic respiration to decrease cellular O2 consumption, and exacerbating hypoxia to improve the efficacy of hypoxia‐activated pre‐drugs. At the same time, the applications of MOF nanocomposites applied to overcome tumor hypoxia in different therapeutic methods at the present stage are described, and finally, the challenges and opportunities in further development of MOF nanocomposites are discussed.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer, Hypoxia, and Metabolism · Metal-Organic Frameworks: Synthesis and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Medical Imaging Department of Shanxi Medical University Taiyuan 030001 P. R. China
Department of Interventional Therapy Shanxi Province Cancer Hospital Shanxi Hospital Affiliated to Cancer Hospital Chinese Academy of Medical Sciences Cancer Hospital Affiliated to Shanxi Medical University Taiyuan 030001 P. R. China
Key Laboratory of Interface Science and Engineering in Advanced Materials Ministry of Education Taiyuan University of Technology Taiyuan 030024 P. R. China
Department of Interventional Therapy Shanxi Provincial People's Hospital Taiyuan 030001 P. R. China
Laboratory of Controllable Preparation and Application of Nanomaterials Laboratory of Cryogenics Technical Institute of Physics and Chemistry Chinese Academy of Sciences Beijing 100190 P. R. China
Funding
National Natural Science Foundation of China · Shanxi-Zheda Institute of Advanced Materials and Chemical Engineering · Shanxi Scholarship Council of China
References (100+)
Show source-provided references
1. 10.1016/j.cub.2020.06.08110.1016/j.cub.2020.06.081 ↗
2. Martin J. D. · Csh. Perspect. Med. · 2016 · 6
3. 10.1016/j.canlet.2016.01.04310.1016/j.canlet.2016.01.043 ↗
4. 10.1152/physrev.00018.201910.1152/physrev.00018.2019 ↗
5. 10.1039/D0NR06271E10.1039/D0NR06271E ↗
6. 10.1002/adhm.20230008910.1002/adhm.202300089 ↗
7. 10.1002/adhm.20230053010.1002/adhm.202300530 ↗
8. 10.1039/C9NR09071A10.1039/C9NR09071A ↗
9. 10.1016/j.biomaterials.2019.11957810.1016/j.biomaterials.2019.119578 ↗
10. 10.1039/D0BM01118E10.1039/D0BM01118E ↗
11. 10.1002/adma.20180020210.1002/adma.201800202 ↗
12. 10.1007/s40820-020-00423-310.1007/s40820-020-00423-3 ↗
13. 10.1021/acsami.9b0573610.1021/acsami.9b05736 ↗
14. 10.7150/thno.3191810.7150/thno.31918 ↗
15. 10.1039/C8CS00688A10.1039/C8CS00688A ↗
16. 10.1002/adma.20190233310.1002/adma.201902333 ↗
17. 10.1002/smll.20190684610.1002/smll.201906846 ↗
18. 10.1021/acsbiomaterials.0c0164410.1021/acsbiomaterials.0c01644 ↗
19. 10.1016/j.jconrel.2019.12.04110.1016/j.jconrel.2019.12.041 ↗
20. 10.1016/j.phrs.2022.10655110.1016/j.phrs.2022.106551 ↗
21. 10.1002/mabi.20210009210.1002/mabi.202100092 ↗
22. 10.1016/j.jconrel.2020.05.02910.1016/j.jconrel.2020.05.029 ↗
23. 10.1016/j.jconrel.2019.12.02810.1016/j.jconrel.2019.12.028 ↗
24. 10.1042/bse043010510.1042/bse0430105 ↗
25. Germain S. · Curr. Opin. Hematol. · 2010 · 17 · 245
26. 10.1186/s12943-020-01288-110.1186/s12943-020-01288-1 ↗
27. 10.1152/physrev.00038.201010.1152/physrev.00038.2010 ↗
28. 10.1016/j.canlet.2020.12.02010.1016/j.canlet.2020.12.020 ↗
29. 10.1007/s10555-018-09777-y10.1007/s10555-018-09777-y ↗
30. 10.1038/s41577-021-00541-y10.1038/s41577-021-00541-y ↗
31. 10.1002/jcb.2768110.1002/jcb.27681 ↗
32. 10.1007/s12094-020-02378-810.1007/s12094-020-02378-8 ↗
33. Han Z. · Am. J. Cancer Res. · 2021 · 11 · 3777
34. 10.3389/fimmu.2019.0227810.3389/fimmu.2019.02278 ↗
35. 10.1038/s41590-022-01379-910.1038/s41590-022-01379-9 ↗
36. 10.1016/j.ccell.2017.08.00410.1016/j.ccell.2017.08.004 ↗
37. 10.1038/onc.2016.22510.1038/onc.2016.225 ↗
38. 10.1152/ajpcell.00207.201510.1152/ajpcell.00207.2015 ↗
39. 10.1080/17460441.2019.161337010.1080/17460441.2019.1613370 ↗
40. 10.1002/med.2177110.1002/med.21771 ↗
41. 10.3390/cells1205079810.3390/cells12050798 ↗
42. 10.1093/cvr/cvq04510.1093/cvr/cvq045 ↗
43. 10.1160/TH06-12-074410.1160/TH06-12-0744 ↗
44. 10.1021/acs.bioconjchem.1c0013110.1021/acs.bioconjchem.1c00131 ↗
45. 10.1158/0008-5472.CAN-08-247010.1158/0008-5472.CAN-08-2470 ↗
46. 10.1007/s10555-007-9064-010.1007/s10555-007-9064-0 ↗
47. 10.3390/ijms2405459510.3390/ijms24054595 ↗
48. 10.3389/fonc.2020.0146210.3389/fonc.2020.01462 ↗
49. 10.1002/anie.20140846410.1002/anie.201408464 ↗
50. 10.1016/j.biomaterials.2018.06.00710.1016/j.biomaterials.2018.06.007 ↗
51. 10.1021/acs.chemmater.8b0432110.1021/acs.chemmater.8b04321 ↗
52. 10.1021/acsami.9b1068510.1021/acsami.9b10685 ↗
53. 10.1126/sciadv.abi482210.1126/sciadv.abi4822 ↗
54. 10.1038/s41598-020-68190-010.1038/s41598-020-68190-0 ↗
55. 10.1021/acsami.9b1503710.1021/acsami.9b15037 ↗
56. 10.1021/acs.nanolett.1c0122010.1021/acs.nanolett.1c01220 ↗
57. 10.1021/acsami.3c0292910.1021/acsami.3c02929 ↗
58. 10.1002/adma.20210397810.1002/adma.202103978 ↗
59. 10.1016/j.jconrel.2021.02.03010.1016/j.jconrel.2021.02.030 ↗
60. 10.1039/D0TB02791J10.1039/D0TB02791J ↗
61. 10.1002/wnan.172010.1002/wnan.1720 ↗
62. 10.1002/smll.20220404710.1002/smll.202204047 ↗
63. 10.1515/hsz-2017-013110.1515/hsz-2017-0131 ↗
64. 10.1021/ja901857210.1021/ja9018572 ↗
65. 10.1021/acsabm.1c0017410.1021/acsabm.1c00174 ↗
66. 10.1002/anie.20190347510.1002/anie.201903475 ↗
67. 10.1039/C7TB00314E10.1039/C7TB00314E ↗
68. 10.1021/acsnano.2c0032710.1021/acsnano.2c00327 ↗
69. 10.1021/la304607710.1021/la3046077 ↗
70. 10.1002/adfm.20200243110.1002/adfm.202002431 ↗
71. 10.1021/acsami.9b1495810.1021/acsami.9b14958 ↗
72. 10.1039/D0NR02800B10.1039/D0NR02800B ↗
73. 10.1186/s12951-022-01436-310.1186/s12951-022-01436-3 ↗
74. 10.1016/j.colsurfb.2022.11260110.1016/j.colsurfb.2022.112601 ↗
75. 10.1016/j.aca.2022.34033510.1016/j.aca.2022.340335 ↗
76. 10.1016/j.biopha.2021.11160610.1016/j.biopha.2021.111606 ↗
77. 10.1002/adma.20190189310.1002/adma.201901893 ↗
78. 10.1002/smtd.20220017810.1002/smtd.202200178 ↗
79. 10.1186/s12951-021-00835-210.1186/s12951-021-00835-2 ↗
80. 10.1021/acsami.0c0853410.1021/acsami.0c08534 ↗
81. 10.1039/D1SC05482A10.1039/D1SC05482A ↗
82. 10.1021/acsami.0c0153910.1021/acsami.0c01539 ↗
83. 10.1002/advs.20190213710.1002/advs.201902137 ↗
84. 10.1039/D1DT03110D10.1039/D1DT03110D ↗
85. 10.1186/s13045-022-01292-610.1186/s13045-022-01292-6 ↗
86. 10.1007/978-3-319-91287-5_2710.1007/978-3-319-91287-5_27 ↗
87. 10.1038/nrc118710.1038/nrc1187 ↗
88. 10.1016/j.jphotobiol.2021.11227410.1016/j.jphotobiol.2021.112274 ↗
89. 10.1021/acsami.9b1811210.1021/acsami.9b18112 ↗
90. 10.1016/j.ejphar.2021.17417810.1016/j.ejphar.2021.174178 ↗
91. 10.1007/s11427-018-9438-y10.1007/s11427-018-9438-y ↗
92. 10.3390/molecules1509612710.3390/molecules15096127 ↗
93. 10.1002/cbic.20190034410.1002/cbic.201900344 ↗
94. 10.1021/acsami.9b0811510.1021/acsami.9b08115 ↗
95. 10.1002/anie.20190271410.1002/anie.201902714 ↗
96. 10.3390/ijms22241340510.3390/ijms222413405 ↗
97. 10.1016/j.semcancer.2022.01.00110.1016/j.semcancer.2022.01.001 ↗
98. 10.1021/acsnano.8b0922110.1021/acsnano.8b09221 ↗
99. 10.1039/C7TB02818K10.1039/C7TB02818K ↗
100. 10.3390/ijms2109336310.3390/ijms21093363 ↗